SUBBU SARMA: Open Payments
NPI 1689661829 · LEES SUMMIT, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$44,776 in 171 payments from 15 companies in 2025. Trend: 2023 $44,727 · 2024 $52,330 · 2025 $44,776
Speaker / faculty: $36,512Travel & lodging: $4,100Food & beverage: $4,006Education: $158
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 48 | $30,083 |
| E.R. Squibb & Sons, L.L.C. | 46 | $12,999 |
| Axsome Therapeutics, Inc. | 11 | $379 |
| Vanda Pharmaceuticals Inc. | 10 | $259 |
| Otsuka America Pharmaceutical, Inc. | 15 | $258 |
| Janssen Pharmaceuticals, Inc | 9 | $163 |
| Alkermes, Inc. | 8 | $158 |
| ABBVIE INC. | 8 | $149 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $100 |
| Neurocrine BioSciences, Inc. | 3 | $64 |
Products named: UZEDY, COBENFY, Auvelity, AUSTEDO XR, ABILIFY ASIMTUFII, ARISTADA, VRAYLAR, FANAPT.
Industry payments across MO — which companies pay providers there.
